India Produces First Badri Cattle Calf Through OPU-IVF Technology
Uttarakhand’s indigenous Badri cattle breed has achieved a major milestone in conservation and genetic improvement, with…
Dryland Congress 2026: Global South Pushes Dryland Agriculture From Ideas to Scale
14 September 2026, New Delhi: The Dryland Congress 2026 concluded in New Delhi with a renewed push to move dryland agric…
Punjab Farmers Plan Five-Day Protest Over MSP, Power and Fertilizer
14 September 2026, Chandigarh: A Punjab farmers’ group announced on September 13 that it will launch five days of …
India Shifts Pesticide Industry to Digital-Only Licensing and Compliance from September 15
14 September 2026, New Delhi: From September 15, 2026, every pesticide manufacturer, importer, seller and distributor op…
Punjab Farmers End Week-Long Chandigarh Protest After Government Accepts Demands
14 September 2026, Chandigarh: Farmer leaders called off a seven-day sit-in at the Chandigarh-Mohali border on September…
Brazil and Argentina Deepen Cooperation on Biological Crop Inputs
14 September 2026, Buenos Aires, Argentina: A Brazilian agricultural delegation traveled to Argentina in early September…
2026年福建农业行业职业技能竞赛（农机修理工）在三明举办
9月5日至6日，2026年福建省农业行业职业技能竞赛(农机修理工)在福建省三明市农业学校举办。本届竞赛由福建省农业农村厅、福建省人力资源和社会保障厅、福建省总工会联合主办，福建省农业机械推广总站、三明市农业机械化发展中心、三明市农业学校…
新荣召开2026年农产品初加工机械化提质增效技术推广项目现场演示会
金秋时节，硕果飘香，正是农产品收获上市、提质增值的关键时节。9月4日上午，我们齐聚在山西省大同市新荣区堡子湾乡拒墙堡村新荣区楷霖粮油有限公司召开2026年新荣区农产品初加工机械化提质增效技术装备示范推广项目现场演示会，参加本次演示会的有…
Novel Food Firms Pausing UK Plans As EU Trade Deal Fuels Regulatory Uncertainty
Food tech startups are pushing the brakes on commercial plans in the UK amid looming regulatory uncertainty caused by an upcoming trade deal with the EU, an open letter has warned.
StockWatch: Novartis Loses More than Market Value After Phase III Failure
Novartis (SIX Swiss: NOVN and NYSE: NVS) lost more than just the roughly $30 billion in market capitalization (share price times the number of outstanding shares) that dried up this past week when the company said its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a Phase III trial.